Quarterly ResultMay 7, 2026, 07:31 AM
Akebia Q1 Net Loss $9.05M; Revenue Down 6.6%; Generic Auryxia Enters Market
AI Summary
Akebia Therapeutics reported a net loss of $9.05 million for the first quarter of 2026, a significant decline from a net income of $6.11 million in the prior year. Total revenues decreased by 6.6% to $53.54 million, primarily due to a drop in product revenue. The company also noted the entry of a generic version of its Auryxia product into the market in March 2026, following its loss of exclusivity in March 2025, which is expected to impact future revenue. Akebia anticipates continued losses and may require additional financing.
Key Highlights
- Net loss was $9.05 million in Q1 2026, compared to a net income of $6.11 million in Q1 2025.
- Total revenues decreased 6.6% to $53.54 million in Q1 2026 from $57.34 million in Q1 2025.
- Product revenue, net, declined to $51.99 million in Q1 2026 from $55.79 million in Q1 2025.
- Basic and diluted EPS was $(0.03) in Q1 2026, down from $0.03 in Q1 2025.
- Teva Pharmaceuticals launched a generic version of Auryxia on March 11, 2026.
- Cash and cash equivalents totaled $162.64 million as of March 31, 2026.
- Net cash used in operating activities increased to $21.21 million in Q1 2026.
- The company expects to incur continued losses and may require additional financing.
Price Impact
More from AKBA